<DOC>
	<DOCNO>NCT02570750</DOCNO>
	<brief_summary>The main purpose study assess effect smoking status success Etanercept therapy patient moderate-to-severe psoriasis .</brief_summary>
	<brief_title>The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis</brief_title>
	<detailed_description>Study hypothesis base follow rationale : - Psoriasis vulgaris chronic inflammatory skin disease several extracutaneous manifestation significant comorbidities ( among others cardiovascular disease , metabolic syndrome , obesity depression ) . - An increased prevalence smoking among psoriasis patient , compare healthy subject , observe several study - More recent study suggest cigarette smoking may trigger development psoriasis oxidative , inflammatory genetic mechanisms.Furthermore , smoke associate clinical severity psoriasis - Smoking also contribute high morbidity mortality smoking related disorder patient There evidence patient psoriasis smoke tend less responsive treatment</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Adult patient age ≥18 year time screen Clinical diagnosis chronic plaque type psoriasis least 6 month determine subject medical history , confirmation diagnosis physical examination investigator Patients schedule dermatologist initiate treatment Etanercept prescribe independently investigator per local clinical practice guideline Stable plaque psoriasis least 2 month prior Baseline Diagnosis severe psoriasis define PASI &gt; 10 Eligible Etanercept treatment accord Summary Product Characteristics ( SmPC ) Smokers smoke &gt; 10 cigarette daily smoker group ( Group 1 ) nonsmoker nonsmoking group ( Group 2 ) Evidence personally sign date informed consent form indicate subject inform pertinent aspect study Previous current treatment antipsoriatic biologic drug , Etanercept , infliximab , adalimumab , ustekinumab , alefacept , efalizumab . Exclusion Criteria accord Enbrel® SmPC , particular attention : hypersensitivity active substance ( etanercept ) excipients ; sepsis risk sepsis , active infection , include chronic localise infection . Positive pregnancy test , breast feeding consider become pregnant study Clinically significant drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>